Unlearn vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI digital twin platform (TwinRCT) replacing placebo arms in clinical trials. $100M+ raised ($50M rounds x2); EMA-qualified PROCOVA for Phase 2/3; FDA positive feedback.
About
Unlearn is an AI company that develops machine learning-generated digital twins of clinical trial participants, enabling pharmaceutical companies to run smaller, faster, and more statistically powerful trials. Its TwinRCT solution uses PROCOVA — a covariate adjustment methodology now officially qualified by the European Medicines Agency for use in Phase 2 and 3 trials with continuous outcomes — to augment or replace traditional placebo control arms with AI-generated synthetic patient profiles. The FDA has provided positive feedback supporting PROCOVA''s use in covariate-adjusted analyses across clinical development. Unlearn has built its strongest traction in neuroscience — Alzheimer''s disease and ALS — where small patient populations and high mortality rates make trial efficiency critical. The company has raised approximately $100M across two $50M funding rounds, with the most recent round in 2024.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.